Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution

@inproceedings{Denoyer2016CopperAA,
  title={Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution},
  author={Delphine Denoyer and Helen B. Pearson and Sharnel A.S. Clatworthy and Zoe M Smith and Paul S Francis and Roxana M. Llanos and Irene Volitakis and Wayne A Phillips and Peter M. Meggyesy and Shashank Masaldan and Michael A. Cater},
  booktitle={Oncotarget},
  year={2016}
}
Copper-ionophores that elevate intracellular bioavailable copper display significant therapeutic utility against prostate cancer cells in vitro and in TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) mice. However, the pharmacological basis for their anticancer activity remains unclear, despite impending clinical trails. Herein we show that intracellular copper levels in prostate cancer, evaluated in vitro and across disease progression in TRAMP mice, were not correlative with copper… CONTINUE READING